Wells Fargo & Company MN Decreases Holdings in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Wells Fargo & Company MN reduced its position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 1.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,304 shares of the company’s stock after selling 1,283 shares during the period. Wells Fargo & Company MN owned about 1.84% of Invesco Biotechnology & Genome ETF worth $4,943,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its position in shares of Invesco Biotechnology & Genome ETF by 30.0% in the 4th quarter. JPMorgan Chase & Co. now owns 650 shares of the company’s stock worth $43,000 after buying an additional 150 shares in the last quarter. Millstone Evans Group LLC purchased a new stake in shares of Invesco Biotechnology & Genome ETF in the fourth quarter valued at about $64,000. Jones Financial Companies Lllp increased its stake in shares of Invesco Biotechnology & Genome ETF by 52.9% during the 4th quarter. Jones Financial Companies Lllp now owns 2,315 shares of the company’s stock worth $154,000 after purchasing an additional 801 shares in the last quarter. Farther Finance Advisors LLC acquired a new position in shares of Invesco Biotechnology & Genome ETF during the 4th quarter worth approximately $161,000. Finally, Jane Street Group LLC purchased a new stake in Invesco Biotechnology & Genome ETF in the 3rd quarter valued at approximately $295,000.

Invesco Biotechnology & Genome ETF Stock Performance

Invesco Biotechnology & Genome ETF stock opened at $59.03 on Monday. Invesco Biotechnology & Genome ETF has a fifty-two week low of $54.52 and a fifty-two week high of $72.84. The stock has a fifty day moving average of $64.03 and a two-hundred day moving average of $67.12. The company has a market capitalization of $212.51 million, a price-to-earnings ratio of 21.05 and a beta of 0.83.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.